Anpac Bio Surpasses 50,000 Case Study Milestone 'Liquid Biopsy Pioneer' Serving Individual, Medical, Insurance & Corporate Customers

News provided by

Anpac Bio-Medical Science Company

18 Oct, 2017, 06:46 IST

SACRAMENTO, California, Oct. 18, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)
International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Described as "game changing", and receiving the, "Breakthrough Innovation Award", at World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from the 50,000+ cases processed to date demonstrate CDA diagnostics consistently detect over 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages.

The company has filed over 200 CDA-related patent applications worldwide – 65+ issued currently; and maintains operations in six sites, employing over 100 people globally.

"Since our company launched in 2008, Anpac Bio has pioneered the 'liquid biopsy' space," states Dr. Yu. "Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia's most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. And as this research has been published and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in great demand. We're now processing CDA tests for individuals, health systems, insurance companies, educational institutions, and corporations. We're very proud that our CDA devices have advanced beyond the laboratory, and are processing real tests for real people – saving lives every day. At this rate, we project to double our CDA cases worldwide and save many more lives in 2018!"

For more information about Anpac Bio please check: www.AnpacBio.com.

Logo - http://mma.prnewswire.com/media/585598/Anpac_Bio_Medical_Science_Co.jpg

Related Links

http://www.AnpacBio.com